This company has shut down. EQRx is no longer operating — its last tracked round was a Post-IPO Equity in 2021.
Explore the Startup GraveyardEQRx is a biotechnology company that focuses on re-engineering the process of drug discovery to make them affordable.
EQRx has raised $1.2B in total funding. The most recent round was Post-IPO Equity. The last funding was announced in December 2021.
EQRx's investors include Franklin Templeton, Andreessen Horowitz, ARCH Venture Partners, Verily, Mubadala.
EQRx is headquartered in Cambridge, United States.
EQRx is a biotechnology company that focuses on re-engineering the process of drug discovery to make them affordable.
EQRx is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"EQRx — Funding & Investors." VCBacked, December 17, 2021, https://www.vcbacked.co/company/eqrx. Accessed August 14, 2026.
VCBacked. (2021). EQRx — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/eqrx
{{cite web |title=EQRx — Funding & Investors |url=https://www.vcbacked.co/company/eqrx |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated